Everything for the customer, everything comes from innovation

  • Active Pharmaceutical Ingredients (APIs) & Intermediates

    Chemexpress focuses on the development of APIs and intermediates of complex chiral drugs with high-tech barriers through the company's specialized and high-standard process research, quality management and project management systems. So far, we have developed over 100 APIs and intermediates, among which 84 products possess the foundation for industrialization. The products cover different fields such as anti-infection, diabetes, and cardio-cerebrovascular disease treatment.

  • Vitamin D Derivatives

    Vitamin D derivatives generally have multiple chiral centers (>6) and have multi-step synthesis (10-20 steps). Their chemical synthesis also involves various special reactions such as chiral synthesis, ozonation and photochemical reaction. Vitamin D derivatives play a vital role in the treatment of rickets, renal osteodystrophy, osteoporosis, psoriasis, secondary hyperparathyroidism, and cancer. At present, the company has a reserve of more than ten Vitamin D derivatives projects, including calcipotriol, idecalcitol, maxacalcitol, paricalcitol, etc. with 2nd DMFs submitted for registration of many intermediates.

  • High-potency Complex Molecular Drugs

    A high potency API generally means a highly active or high-potency drug with a dosage of less than 10 mg/day or with an occupational exposure limit (OEL) less than 10 μg/m3. High-potency APIs are usually drug molecules with complex structures with high value. They can act on the targets more selectively than other APIs and feature low dosage and high efficacy. At present, Chemexpress resides at advanced levels in the industry in terms of product quality, cost-effectiveness, and research timelines of many high-potency API projects.

  • Antibody-drug Conjugates (ADCs)

    ADC can reduce the adverse effects of the cytotoxic anti-tumor agents and improve the selectivity of tumor treatment. In addition, it serves as a better solution to deal with the drug resistance of targeted monoclonal antibodies. Its emergence fills the gap between antibody drugs and traditional chemotherapeutics, improving the drug specificity and the therapeutic window. As one of the pioneers carrying out the development and research of ADC in China, we have completed structure, polymorphs confirmation and impurity structure confirmation for some toxins, linkers and toxins-linkers. We have obtained the manufacturing process with stable quality through the implementation of a multi-chiral control strategy, thus achieving kilogram level supply.

  • Building Blocks & Reference Compounds

    Chemexpress independently develops, customizes, synthesize and optimize large number of compounds. Presently, we have synthesized over 10,000 kinds of building blocks and reference compounds with the scale varying from milligram to kilogram level. It includes product series of quinolines, azaindoles, tetralones, piperazines, pyrrolidines, cyclobutanes, spirocyclics, etc. These products are used in various stages of drug discovery, including pathway study, target discovery screening and lead optimization of compounds for preclinical studies.


    10,000+ self-designed and synthesized building blocks and reference compounds

    35,000+ in-stock compounds, ranging from mg to kg level, available for sustainable supply at high quality

    80+ product series, including heterocyclic compounds, amino acid and its derivatives, boronic acid and its ester, chiral compounds, fluorine-containing compounds, reagents for organic synthesis, etc., covering all commonly used chemical structures for small molecule drug development

    1,500+ spot catalyst ligands, including classic common catalyst ligands and new ones with specific performance

    50,000+ building blocks deliverable within one to two weeks